Effect of Ranolazine on A1C and Glucose Levels in Hyperglycemic Patients With Non-ST Elevation Acute Coronary Syndrome
Open Access
- 31 March 2010
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 33 (6) , 1163-1168
Abstract
OBJECTIVE: We determined the relationships between glycemia at randomization, concurrent antidiabetic therapy, and change in A1C and fasting plasma glucose (FPG) in patients with diabetes receiving standard treatment for diabetes and randomized to ranolazine or placebo within the MERLIN-TIMI-36 (MERLIN) study. Ranolazine is a novel first-in-class drug approved for treating angina pectoris. RESEARCH DESIGN AND METHODS: Randomization and 4-month glycemic and antidiabetes drug usage data from MERLIN were analyzed using Spotfire and SAS version 9.1 software. RESULTS: In patients with diabetes and A1C of ≥8–10% at randomization (n = 171), there was an absolute A1C reduction in the ranolazine group of 1.2% (95% CI −1.4 to −1.0), and the placebo-adjusted (n = 182) decrease in A1C by ranolazine was 0.59% (95% CI −0.99 to −0.20, P < 0.001). In patients with FPG of 150–400 mg/dl at randomization, ranolazine (n = 131) compared with placebo (n = 147) reduced FPG by 25.7 mg/dl (95% CI −43.3 to −8.1, P = 0.001). When changes in either A1C or FPG were correlated to A1C or FPG at randomization, the slopes were significantly steeper for ranolazine than placebo (A1C, P = 0.046; FPG, P < 0.001), indicating that lowering of A1C and FPG by ranolazine is related to hyperglycemia at randomization. Ranolazine, compared with placebo, was not associated with serious hypoglycemic events, associated with significant changes in concurrent antidiabetic therapy, or dependent on a history of angina. CONCLUSIONS: Ranolazine, when added to concurrent antidiabetes treatment, lowers FPG and A1C in patients with cardiovascular disease and poorly controlled diabetes.Keywords
This publication has 21 references indexed in Scilit:
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- Pathophysiology and pharmacology of the cardiac “late sodium current”Pharmacology & Therapeutics, 2008
- Non-Insulin Antidiabetic Therapy in Cardiac Patients: Current Problems and Future Prospects2008
- Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factorsThe Lancet, 2007
- Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering EfficacyDiabetes Care, 2006
- Antianginal Efficacy of Ranolazine When Added to Treatment With AmlodipineJACC, 2006
- Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non–ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trialAmerican Heart Journal, 2006
- Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazineHeart, 2006
- Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetesEuropean Heart Journal, 2005
- Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe anginaJACC, 2004